---
document_datetime: 2025-12-21 11:52:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/fabhalta.html
document_name: fabhalta.html
version: success
processing_time: 0.1434062
conversion_datetime: 2025-12-24 07:11:18.620693
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Fabhalta

[RSS](/en/individual-human-medicine.xml/240138)

##### Authorised

This medicine is authorised for use in the European Union

iptacopan Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Fabhalta](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-80584)
- [More information on Fabhalta](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Fabhalta is a medicine used to treat:

- haemolytic anaemia in adults with paroxysmal nocturnal haemoglobinuria (PNH). PNH is a disease in which the excessive breakdown of blood cells results in anaemia (low levels of haemoglobin, the protein in red blood cells that carries oxygen around the body), thrombosis (blood clots in blood vessels), pancytopenia (low levels of blood cells) and dark urine (due to large amounts of haemoglobin being released into the urine).
- complement 3 glomerulopathy (C3G) in adults, either in combination with a RAS inhibitor (a medicine that acts on the renin-angiotensin system) or alone in patients who cannot take a RAS inhibitor. C3G is a disease in which progressive damage to the kidneys prevent them from filtering the blood correctly, leading to toxin buildup, reduced urine production and swelling.

PNH and C3G are rare, and Fabhalta was designated an 'orphan medicine' (a medicine used in rare diseases). Further information on the orphan designations can be found on the EMA website (PNH: 4 June 2020; C3G: 4 December 2018).

Fabhalta contains the active substance iptacopan.

Expand section

Collapse section

## How is Fabhalta used?

Fabhalta is available as capsules to be taken by mouth twice a day.

If one or more doses are missed, the medicine should be taken as soon as possible. In patients with PNH, if multiple doses are missed, patients should be monitored for signs and symptoms of haemolysis (an abnormal breakdown of red blood cells).

The medicine can only be obtained with a prescription.

For more information about using Fabhalta, see the package leaflet or contact your doctor or pharmacist.

## How does Fabhalta work?

The complement system is a group of proteins that is part of the immune system (the body's natural defences). In patients with PNH and C3G, the complement system is over-active, damaging the patients' own cells, particularly red blood cells in PNH and kidney cells in C3G.

The active substance in Fabhalta, iptacopan, blocks a protein of the complement system called 'factor B'. By blocking factor B, Fabhalta prevents the complement system from damaging red blood cells in PNH and kidney cells in C3G, thereby helping to relieve the symptoms of these diseases.

## What benefits of Fabhalta have been shown in studies?

**PNH**

Fabhalta was shown to be effective at increasing haemoglobin levels and reducing the need for blood transfusions in one main study involving 97 patients with PNH.

Patients in the study had been previously treated with ravulizumab or eculizumab (other medicines for PNH) for at least 6 months and still had anaemia. Patients took either Fabhalta or continued their treatment with ravulizumab or eculizumab. After 24 weeks of treatment, the percentage of patients who achieved an increase in haemoglobin levels of at least 2 g/dL without blood transfusions was around 82% for patients on Fabhalta, compared with 2% of patients continuing on ravulizumab or eculizumab. Around 69% of patients taking Fabhalta achieved haemoglobin levels of at least 12 g/dL without blood transfusions, compared with around 2% of the patients taking ravulizumab or eculizumab.

Data from an additional study supported the use of Fabhalta in patients with PNH who had not been previously treated.

**C3G**

Fabhalta was shown to be more effective than placebo at reducing kidney damage in one main study involving 74 patients with C3G. Patients in the study were already treated for C3G with other medicines such as RAS inhibitors and immunosuppressants (corticosteroids, mycophenolate mofetil or mycophenolate sodium).

The main measure of effectiveness was protein levels in the urine of patients. As healthy kidneys keep nearly all proteins in the blood, the presence of proteins in urine indicates kidney damage.

After 6 months of treatment, patients given Fabhalta had an approximately 35% reduction in their urine protein levels compared with those given placebo. This effect was maintained after 12 months of treatment.

## What are the risks associated with Fabhalta?

For the full list of side effects and restrictions with Fabhalta, see the package leaflet.

In patients with PNH, the most common side effects with Fabhalta (which may affect more than 1 in 10 people) include upper respiratory tract (nose and throat) infection, headache and diarrhoea. The most common serious side effect with Fabhalta is urinary tract infection (infection of the parts of the body that collect and pass out urine), which may affect up to 1 in 10 patients.

In patients with C3G, the most common side effects with Fabhalta (which may affect more than 1 in 10 people) include upper respiratory tract infection. The most common serious side effect is infection with pneumococcal bacteria, which may affect up to 1 in 10 people.

Based on how Fabhalta works, it may increase the risk of infections. Fabhalta must not be used by patients who have an ongoing infection caused by so-called encapsulated bacteria, including *Neisseria meningitidis* , *Streptococcus pneumoniae* and *Haemophilus influenzae* type B. It must also not be used by patients who are not currently vaccinated against *N. meningitidis* and *S.pneumoniae* unless the risk of delaying treatment outweighs the risk of developing an infection from these bacteria.

## Why is Fabhalta authorised in the EU?

Fabhalta was shown to be effective at increasing haemoglobin levels and reducing the need for blood transfusions in patients with PNH. It was also shown to reduce the accumulation of proteins in the urine of patients with C3G, which suggests reduced kidney damage. The most common side effects are considered inconvenient but are not expected to pose a risk to patients. The European Medicines Agency therefore decided that Fabhalta's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Fabhalta?

The company that markets Fabhalta will provide doctors and patients with educational materials on the risk of infection by encapsulated bacteria and the need for patients to receive appropriate vaccination. For patients with PNH, the materials also include information on the risk of serious haemolysis when stopping treatment with Fabhalta.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fabhalta have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Fabhalta are continuously monitored. Suspected side effects reported with Fabhalta are carefully evaluated and any necessary action taken to protect patients.

## Other information about Fabhalta

Fabhalta received a marketing authorisation valid throughout the EU on 17 May 2024.

Fabhalta : EPAR - Medicine overview

English (EN) (154.25 KB - PDF)

**First published:** 14/06/2024

**Last updated:** 11/04/2025

[View](/en/documents/overview/fabhalta-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (179.3 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/bg/documents/overview/fabhalta-epar-medicine-overview_bg.pdf)

español (ES) (153.25 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/es/documents/overview/fabhalta-epar-medicine-overview_es.pdf)

čeština (CS) (180.6 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/cs/documents/overview/fabhalta-epar-medicine-overview_cs.pdf)

dansk (DA) (152.06 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/da/documents/overview/fabhalta-epar-medicine-overview_da.pdf)

Deutsch (DE) (156.73 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/de/documents/overview/fabhalta-epar-medicine-overview_de.pdf)

eesti keel (ET) (152.12 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/et/documents/overview/fabhalta-epar-medicine-overview_et.pdf)

ελληνικά (EL) (187.84 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/el/documents/overview/fabhalta-epar-medicine-overview_el.pdf)

français (FR) (154.54 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/fr/documents/overview/fabhalta-epar-medicine-overview_fr.pdf)

hrvatski (HR) (177.63 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/hr/documents/overview/fabhalta-epar-medicine-overview_hr.pdf)

italiano (IT) (151.89 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/it/documents/overview/fabhalta-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (193.94 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/lv/documents/overview/fabhalta-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (178.31 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/lt/documents/overview/fabhalta-epar-medicine-overview_lt.pdf)

magyar (HU) (178.87 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/hu/documents/overview/fabhalta-epar-medicine-overview_hu.pdf)

Malti (MT) (180.59 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/mt/documents/overview/fabhalta-epar-medicine-overview_mt.pdf)

Nederlands (NL) (153.22 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/nl/documents/overview/fabhalta-epar-medicine-overview_nl.pdf)

polski (PL) (179.24 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/pl/documents/overview/fabhalta-epar-medicine-overview_pl.pdf)

português (PT) (154.54 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/pt/documents/overview/fabhalta-epar-medicine-overview_pt.pdf)

română (RO) (176.11 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/ro/documents/overview/fabhalta-epar-medicine-overview_ro.pdf)

slovenčina (SK) (179.34 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/sk/documents/overview/fabhalta-epar-medicine-overview_sk.pdf)

slovenščina (SL) (177.54 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/sl/documents/overview/fabhalta-epar-medicine-overview_sl.pdf)

Suomi (FI) (151.02 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/fi/documents/overview/fabhalta-epar-medicine-overview_fi.pdf)

svenska (SV) (152.22 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/sv/documents/overview/fabhalta-epar-medicine-overview_sv.pdf)

Fabhalta : EPAR - Risk-management-plan

English (EN) (868.38 KB - PDF)

**First published:** 14/06/2024

**Last updated:** 11/04/2025

[View](/en/documents/rmp/fabhalta-epar-risk-management-plan_en.pdf)

## Product information

Fabhalta : EPAR - Product information

English (EN) (544.63 KB - PDF)

**First published:** 14/06/2024

**Last updated:** 19/12/2025

[View](/en/documents/product-information/fabhalta-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-588)

български (BG) (648.76 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/bg/documents/product-information/fabhalta-epar-product-information_bg.pdf)

español (ES) (597.87 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/es/documents/product-information/fabhalta-epar-product-information_es.pdf)

čeština (CS) (591.91 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/cs/documents/product-information/fabhalta-epar-product-information_cs.pdf)

dansk (DA) (597.02 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/da/documents/product-information/fabhalta-epar-product-information_da.pdf)

Deutsch (DE) (578.75 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/de/documents/product-information/fabhalta-epar-product-information_de.pdf)

eesti keel (ET) (574.3 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/et/documents/product-information/fabhalta-epar-product-information_et.pdf)

ελληνικά (EL) (628.68 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/el/documents/product-information/fabhalta-epar-product-information_el.pdf)

français (FR) (616.06 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/fr/documents/product-information/fabhalta-epar-product-information_fr.pdf)

hrvatski (HR) (641.71 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/hr/documents/product-information/fabhalta-epar-product-information_hr.pdf)

íslenska (IS) (607.02 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/is/documents/product-information/fabhalta-epar-product-information_is.pdf)

italiano (IT) (601.14 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/it/documents/product-information/fabhalta-epar-product-information_it.pdf)

latviešu valoda (LV) (613.46 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/lv/documents/product-information/fabhalta-epar-product-information_lv.pdf)

lietuvių kalba (LT) (635 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/lt/documents/product-information/fabhalta-epar-product-information_lt.pdf)

magyar (HU) (600.88 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/hu/documents/product-information/fabhalta-epar-product-information_hu.pdf)

Malti (MT) (670.41 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/mt/documents/product-information/fabhalta-epar-product-information_mt.pdf)

Nederlands (NL) (568.29 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/nl/documents/product-information/fabhalta-epar-product-information_nl.pdf)

norsk (NO) (565.28 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/no/documents/product-information/fabhalta-epar-product-information_no.pdf)

polski (PL) (664.4 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/pl/documents/product-information/fabhalta-epar-product-information_pl.pdf)

português (PT) (618.71 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/pt/documents/product-information/fabhalta-epar-product-information_pt.pdf)

română (RO) (607.56 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/ro/documents/product-information/fabhalta-epar-product-information_ro.pdf)

slovenčina (SK) (637.07 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/sk/documents/product-information/fabhalta-epar-product-information_sk.pdf)

slovenščina (SL) (609.37 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/sl/documents/product-information/fabhalta-epar-product-information_sl.pdf)

Suomi (FI) (532.21 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/fi/documents/product-information/fabhalta-epar-product-information_fi.pdf)

svenska (SV) (591.78 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

19/12/2025

[View](/sv/documents/product-information/fabhalta-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000319878 19/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Fabhalta : EPAR - All authorised presentations

English (EN) (70.33 KB - PDF)

**First published:** 14/06/2024

**Last updated:** 11/04/2025

[View](/en/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-544)

български (BG) (76.08 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/bg/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_bg.pdf)

español (ES) (70.97 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/es/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_es.pdf)

čeština (CS) (72.46 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/cs/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (72.47 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/da/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (72.08 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/de/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (70 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/et/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (73.38 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/el/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_el.pdf)

français (FR) (70.08 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/fr/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (70.41 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/hr/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (72.96 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/is/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_is.pdf)

italiano (IT) (71.49 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/it/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (73.62 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/lv/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (73.03 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/lt/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (73.21 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/hu/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (74.06 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/mt/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (69.21 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/nl/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (72.37 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/no/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_no.pdf)

polski (PL) (72.18 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/pl/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_pl.pdf)

português (PT) (70.53 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/pt/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_pt.pdf)

română (RO) (70.63 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/ro/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (72.16 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/sk/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (70.18 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/sl/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (70.06 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/fi/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (72.45 KB - PDF)

**First published:**

14/06/2024

**Last updated:**

11/04/2025

[View](/sv/documents/all-authorised-presentations/fabhalta-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Fabhalta Active substance iptacopan hydrochloride monohydrate International non-proprietary name (INN) or common name iptacopan Therapeutic area (MeSH) Hemoglobinuria, Paroxysmal Anatomical therapeutic chemical (ATC) code L04A

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Paroxysmal nocturnal haemoglobinuria

Fabhalta is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.

Complement 3 glomerulopathy

Fabhalta is indicated for the treatment of adult patients with complement 3 glomerulopathy (C3G) in combination with a renin-angiotensin system (RAS) inhibitor, or in patients who are RAS-inhibitor intolerant, or for whom a RAS inhibitor is contraindicated (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/005764

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Opinion adopted 21/03/2024 Marketing authorisation issued 17/05/2024 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Fabhalta : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (148.76 KB - PDF)

**First published:** 20/02/2025

**Last updated:** 19/12/2025

[View](/en/documents/procedural-steps-after/fabhalta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Fabhalta : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (156.07 KB - PDF)

**First published:** 07/10/2024

**Last updated:** 11/04/2025

[View](/en/documents/procedural-steps-after/fabhalta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Fabhalta : Orphan maintenance assessment report - post authorisation

Adopted

Reference Number: EMA/OD/0000224423

English (EN) (287.01 KB - PDF)

**First published:** 11/04/2025

[View](/en/documents/orphan-maintenance-report-post/fabhalta-orphan-maintenance-assessment-report-post-authorisation_en.pdf)

Fabhalta-H-C-005764-II-0001 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/96410/2025

English (EN) (5.03 MB - PDF)

**First published:** 11/04/2025

[View](/en/documents/variation-report/fabhalta-h-c-005764-ii-0001-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Fabhalta (II-01)

Adopted

Reference Number: EMA/CHMP/327/2025

English (EN) (124.35 KB - PDF)

**First published:** 28/02/2025

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-fabhalta-ii-01_en.pdf)

## Initial marketing authorisation documents

Fabhalta : Orphan maintenance assessment report

Reference Number: EMA/OD/0000141229

English (EN) (492.24 KB - PDF)

**First published:** 14/06/2024

[View](/en/documents/orphan-maintenance-report/fabhalta-orphan-maintenance-assessment-report_en.pdf)

Fabhalta : Public assessment report

Adopted

Reference Number: EMA/170439/2024

English (EN) (7.04 MB - PDF)

**First published:** 14/06/2024

[View](/en/documents/assessment-report/fabhalta-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Fabhalta

Adopted

Reference Number: EMA/CHMP/54481/2024

English (EN) (101.99 KB - PDF)

**First published:** 22/03/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-fabhalta_en.pdf)

#### News on Fabhalta

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-february-2025) 28/02/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024) 22/03/2024

[First oral monotherapy for patients with paroxysmal nocturnal haemoglobinuria](/en/news/first-oral-monotherapy-patients-paroxysmal-nocturnal-haemoglobinuria) 22/03/2024

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Fabhalta : : EPAR - Product information - tracked changes

English (EN) (353.06 KB - DOCX)

**First published:** 29/10/2025

[View](/en/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-55)

български (BG) (355.94 KB - DOCX)

**First published:**

29/10/2025

[View](/bg/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_bg.docx)

español (ES) (329.73 KB - DOCX)

**First published:**

29/10/2025

[View](/es/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_es.docx)

čeština (CS) (333.31 KB - DOCX)

**First published:**

29/10/2025

[View](/cs/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (322.3 KB - DOCX)

**First published:**

29/10/2025

[View](/da/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (332.13 KB - DOCX)

**First published:**

29/10/2025

[View](/de/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (325.36 KB - DOCX)

**First published:**

29/10/2025

[View](/et/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (341.67 KB - DOCX)

**First published:**

29/10/2025

[View](/el/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_el.docx)

français (FR) (305.31 KB - DOCX)

**First published:**

29/10/2025

[View](/fr/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (354.55 KB - DOCX)

**First published:**

29/10/2025

[View](/hr/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (347 KB - DOCX)

**First published:**

29/10/2025

[View](/is/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_is.docx)

italiano (IT) (340.94 KB - DOCX)

**First published:**

29/10/2025

[View](/it/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (295.44 KB - DOCX)

**First published:**

29/10/2025

[View](/lv/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (349.34 KB - DOCX)

**First published:**

29/10/2025

[View](/lt/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (325.23 KB - DOCX)

**First published:**

29/10/2025

[View](/hu/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (319.18 KB - DOCX)

**First published:**

29/10/2025

[View](/mt/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (317.42 KB - DOCX)

**First published:**

29/10/2025

[View](/nl/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (320.9 KB - DOCX)

**First published:**

29/10/2025

[View](/no/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_no.docx)

polski (PL) (348.68 KB - DOCX)

**First published:**

29/10/2025

[View](/pl/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_pl.docx)

português (PT) (351.11 KB - DOCX)

**First published:**

29/10/2025

[View](/pt/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_pt.docx)

română (RO) (331.93 KB - DOCX)

**First published:**

29/10/2025

[View](/ro/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (343.46 KB - DOCX)

**First published:**

29/10/2025

[View](/sk/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (350.24 KB - DOCX)

**First published:**

29/10/2025

[View](/sl/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (256.06 KB - DOCX)

**First published:**

29/10/2025

[View](/fi/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (318.56 KB - DOCX)

**First published:**

29/10/2025

[View](/sv/documents/product-information-tracked-changes/fabhalta-epar-product-information-tracked-changes_sv.docx)

#### More information on Fabhalta

- [EU/3/20/2281 - orphan designation for treatment of paroxysmal nocturnal haemoglobinuria](/en/medicines/human/orphan-designations/eu-3-20-2281)
- [EMEA-002705-PIP03-20-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002705-pip03-20-m01)
- [EMEA-002705-PIP06-23 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002705-pip06-23)

**This page was last updated on** 19/12/2025

## Share this page

[Back to top](#main-content)